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Abstract: In this study, the biocompatibility of a calcium
phosphate (CaP) cement incorporating poly (D,L-lactic-co-
glycolic acid) (PLGA) microparticles was evaluated in a
subcutaneous implantation model in rats. Short-term bio-
compatibility was assessed using pure CaP discs and CaP
discs incorporating PLGA microparticles (20% w/w) with
and without preincubation in water. Long-term biocompati-
bility was assessed using CaP discs incorporating varying
amounts (5, 10, or 20% w/w) and diameter sizes (small, 0–
50 lm; medium, 51–100 lm, or large, 101–200 lm) of PLGA
microparticles. The short-term biocompatibility results
showed a mild tissue response for all implant formula-
tions, irrespective of disc preincubation, during the early
implantation periods up to 12 days. Quantitative histologi-
cal evaluation revealed that the different implant formula-
tions induced the formation of similar fibrous tissue cap-
sules and interfaces. The results concerning long-term bio-
compatibility showed that all implants were surrounded
by a thin connective tissue capsule (<10 layers of fibro-
blasts). Additionally, no significant differences in capsule
and interface scores were observed between the different
implant formulations. The implants containing 20% PLGA
with medium- and large-sized microparticles showed fi-
brous tissue ingrowth throughout the implants, indicating
PLGA degradation and interconnectivity of the pores. The
results demonstrate that CaP/PLGA composites evoke a
minimal inflammatory response. The implants containing
20% PLGA with medium- and large-sized microparticles
showed fibrous tissue ingrowth after 12- and 24-weeks
indicating PLGA degradation and interconnectivity of the
pores. Therefore, CaP/PLGA composites can be regarded
as biocompatible biomaterials with potential for bone tis-
sue engineering and advantageous possibilities of the
microparticles regarding material porosity.  2008 Wiley
Periodicals, Inc. J Biomed Mater Res 87A: 760–769, 2008
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nectivity
INTRODUCTION
The filling of bone defects resulting from trauma
or surgical resection of tumors requires the availabil-
ity of safe and reliable synthetic bone substitutes,
since obtaining autologous bone is accompanied
with the known disadvantages of donor site morbid-
ity, increased operative time, and insufficient vol-
umes. Calcium phosphate (CaP) cements have been
proven to be useful as bone substitutes at nonload
bearing sites.1–4 Previous work on CaP cement has
shown that if it consists of a mixture of powder and
liquid, this CaP cement becomes injectable, and
hence can be shaped perfectly according to the
defect dimension in situ.5–8 Porosity can be created
by incorporating degradable poly (D,L-lactic-co-gly-
colic acid) (PLGA) microparticles in the CaP cement
to enhance tissue ingrowth in the CaP cement.9,10
PLGA microparticles will be hydrolyzed in vivo and
as a consequence create microporosity. PLGA poly-
mers are interesting due to degradation properties,
which can be tailored by changing molecular weight,
tacticity, and lactic to glycolic ratio.11 Although a
previous study with various small-sized CaP/PLGA
composite implants (0, 15, 30, or 50% w/w PLGA
microparticles) showed an excellent bone response,12
additional studies to the biocompatibility of CaP/
PLGA implants have to be performed to exclude
that the incorporated PLGA microparticles evoke an
inflammatory response during their degradation. In
the design of such an experiment, it has to be
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included that PLGA microparticle size can affect the
foreign body reaction at the surface of the micropar-
ticles.13 Also, by varying the amounts and diameter
sizes of PLGA microparticles a threshold for inter-
connectivity can be determined. Furthermore, these
PLGA microparticles can be loaded with growth fac-
tors to stimulate bone formation and cement resorp-
tion in future applications.14,15
Also, the biocompatibility of CaP cement could be
improved by preincubation in water. Previous
research resulted in a better cellular response after
preincubation in vitro,11 which could also have an
effect on the final in vivo tissue response.
In view of the above mentioned, this study
focused at the biocompatibility of CaP cement incor-
porating PLGA microparticles in a subcutaneous im-
plantation model in rats. A subcutaneous location
was proven before to be an appropriate location to
evaluate the inflammatory reaction associated with
CaP cement.7 Short-term biocompatibility was
assessed using CaP discs and CaP discs incorporat-
ing PLGA microparticles (20% w/w) with and with-
out preincubation in water. Long-term biocompati-
bility was assessed using CaP discs incorporating
various amounts (5, 10, or 20% w/w) and diameter
sizes (small, 0–50 lm; medium, 51–100 lm, or large,
101–200 lm) of PLGA microparticles.
MATERIALS AND METHODS
Substrates
The CaP cement Calcibon1 (Merck Biomaterial GmbH,
Darmstadt, Germany) was used, which has a chemical
composition of 61% a-TCP, 26% CaHPO4, 10% CaCO3, and
3% PHA (a-TCP is alpha tri-calcium phosphate, PHA is
precipitated hydroxyapatite). An aqueous solution of 1%
Na2HPO4 was used as the liquid component. The used liq-
uid/powder ratio was 0.35 mL/g. Before usage, the
cement powder was sterilized by g-radiation with 25 kGy
(Isotron B.V., Ede, The Netherlands) The cement liquid
was filter-sterilized though a sterile 0.2-lm filter.
PLGA microparticles
PLGA (Purasorb1, Purac, Gorinchem, The Netherlands)
with a molecular weight of 48 kDa and a lactic to glycolic
acid ratio of 50:50 was used. PLGA microparticles were
prepared using a (water/oil/water) double emulsion sol-
vent evaporation technique. The microparticles were pro-
duced by solving 1.0 g PLGA in 4 mL of dichloromethane
(DCM) inside a glass tube. After dissolution, 500 lL deion-
ized water was added to this mixture and emulsified for
60 s on a vortexer. Subsequently, 6 mL 0.3% aqueous poly
vinyl alcohol (PVA) solution was added and vortexed for
another 60 s to produce the second emulsion. After vortex-
ing, the content of the glass tube was transferred to a 1000 mL
beaker and another 394 mL of 0.3% PVA was added
slowly under continuous stirring. This was directly fol-
lowed by adding 400 mL of a 2% isopropylic alcohol (IPA)
solution. The suspension was stirred for 1 h. After stirring,
the microparticles were allowed to settle for 15 min and
the solution was decanted. The microparticle suspension
was centrifuged, and the clear solution at the top was dec-
anted. Then 5 mL of deionized water was added, the
microparticles were washed, centrifuged and the solution
was aspirated. Finally, the microparticles were frozen,
freeze-dried for 24 h and stored under argon at 2208C.
For the short-term biocompatibility study, PLGA micropar-
ticles ranging from 5 to 200 lm were used with an average
diameter of 33 lm. For the long-term biocompatibility
study, microparticles were sieved with a sieve shaker
(Retsch GmbH, Haan, Germany) with 50, 100, and 200 lm
diameter sieves to obtain batches of small (0–50 lm), me-
dium (51–100 lm), and large (101–200 lm) PLGA micro-
particles.
Pre-set sample preparation
The discs were prepared by adding 350 lL cement liq-
uid (1% w/w aqueous solution of Na2HPO4) to a 1000 mg
CaP cement powder or CaP/PLGA mixture in a 2 mL sy-
ringe (Becton Dickinson, Alphen a/d Rijn, The Nether-
lands). The syringe was closed with an injection plunger
and placed in a commercially available mechanical mixing
apparatus as used for the preparation of dental amalgam
TABLE I
Overview of the CaP/PLGA Disc Formulations
Method
PLGA
Amount
Size
(lm)
Short-term
Biocompatibility
(2,4,8 and 12 days)
CaP0 — 0–200
CaP0/PLGA 20%
CaP8 —
CaP8/PLGA 20%
Long-term
Biocompatibility
(12 and 24 weeks)
CaP0/PLGA 5% 0–50
51–100
101–200
10% 0–50
51–100
101–200
20% 0–50
51–100
101–200
Figure 1. Schematic drawing of a CaP/PLGA implant
showing the four predetermined areas used in the histo-
logical evaluation.
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and dental cements (Silamat, Ivoclar Vivadent AG, Schaan,
Liechtenstein). After mixing for 15 s, the plunger was
removed and the cement/composite was injected in teflon
moulds to ensure a standardized shape of the specimens.
The discs (2.4 mm height and 6 mm diameter) were
removed from the moulds after setting of the cement at
room temperature. Discs were used without (CaP0) and
with (CaP8) preincubation in water (8 weeks immersion
on a rotating plate with water, refreshing three times a
week at room temperature).
CaP/PLGA microparticle composites
Various CaP/PLGA composites were created by adding
PLGA microparticles to the CaP cement. CaP cement com-
posites with 5, 10, or 20% w/w PLGA and small, medium,
or large microparticle diameter sizes were prepared (Table
I). The total porosity of the different CaP/PLGA compo-
sites was determined by correlating the weight of CaP
discs with the weight of CaP/PLGA discs after placement
of the samples in a furnace at 6508C for 2 h to remove the
PLGA microparticles.16 Afterwards, samples were ana-
lyzed using microcomputed tomography (lCT) (SkyScan
1172 high-resolution micro-CT, SkyScan, Kontich, Bel-
gium). High-resolution scanning was performed at energy
of 100 kV and intensity of 98 lA. Cone beam reconstruc-
tion (version 2.15, Skyscan1) was done. Also, the chemical
composition of the samples was evaluated by crushing the
samples with a mortar, until the discs were reduced to
powder. The powder was then analyzed by using X-ray
diffraction using a u–2u diffractometer (XRD, Philips
PW3710, Eindhoven, the Netherlands) using a CuKa-radia-
tion of 1.5418 A˚ wavelength. The positions and intensities
of the XRD peaks were used to identify the underlying
structure (phase) of the samples.
Implantation
Fifty-two male Wistar rats (100–120 g) were used for
subcutaneous implantation. The rats received four
implants each, two on each side of the vertical column.
Short-term biocompatibility was assessed using four differ-
ent implants (n 5 6) with variation in implant composition
and preincubation (Table I), and implantation periods of 2,
4, 8, and 12 days. Long-term biocompatibility was assessed
using nine different implants (n 5 6) with variation in
PLGA microparticle amount and size (Table I), and im-
plantation periods of 12 and 24 weeks.
Surgery was performed under general inhalation anes-
thesia with a combination of isoflurane, nitrous oxide, and
oxygen. For reasons of reliability, implant randomization
was applied regarding location. To insert the implants, the
TABLE II
Histological Grading Scale for Soft-Tissue Implants
Evaluation Response Score
Capsule quantitatively 1–4 fibroblasts 4
5–9 fibroblasts 3
10–30 fibroblasts 2
>30 fibroblasts 1
Not applicable 0
Capsule qualitatively Capsule is fibrous, mature, not dense, resembling connective or fat tissue in the
noninjured regions
4
Capsule tissue is fibrous but immature, showing fibroblasts and little collagen 3
Capsule tissue is granulous and dense, containing both fibroblasts and many
inflammatery cells
2
Capsule consists of masses of inflammatory cells with little or no signs of connective
tissue organization
1
Cannot be evaluated because of infection or other factors not necessarily related to the
material
0
Interface qualitatively Fibroblasts contact the implant surface without the presence of macrophages or
leucocytes
4
Scattered focl of macrophages and leucocytes are present 3
One layer of macrophages and leucocytes are present 2
Multiple layers of macrophages and leucocytes present 1
Cannot be evaluated because of infection or other factors not necessarily related to the
material
0
Figure 2. Microporosity (in %) of the different implant
formulations. The 20% PLGA 0–200 lm sizes were used
for the early implantation periods (short-term biocompati-
bility) (CaP0/PGLA and CaP8/PLGA). All other formula-
tions were used for 12- and 24-weeks implantation (long-
term biocompatibility).
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animals were immobilized and placed in a ventral posi-
tion. The back of the animals was shaved, washed, and
disinfected with povidone-iodine. Subsequently, four small
longitudinal incisions (two on each site of the vertebral
column) were made. Lateral to each incision, a subcutane-
ous pocket was created using blunt dissection. After place-
ment of the implants, the skin was closed using staples
(Agraven1, InstruVet BV, Cuijk, the Netherlands). At the
end of each implantation period, the rats were sacrificed
using CO2-suffication.
Histology
Implants with surrounding tissue were retrieved and
prepared for histological evaluation. The samples were
fixed in 4% formalin solution (pH 5 7.4), dehydrated in a
graded series of ethanol and embedded in methylmetha-
crylate. Following polymerization, 10-lm thick sections
were prepared using a sawing microtome technique.17 The
sections were stained with methylene blue and basic fuch-
sin and investigated with a light microscope to examine
the amount of tissue inflammation or bone formation. The
quantitative evaluation of the fibrous capsule was done in
four predetermined fields using a histological grading
scale for soft-tissue implants (Fig. 1 and Table II).18 The
presented data represent the average of these four mea-
surements.
Figure 3. X-ray diffraction (XRD) patterns of the calcium
phosphate cement discs. The XRD powder patterns of as-
prepared (CaP0) and preincubated discs (CaP8), both
before and after subcutaneous implantation for 12 days.
(* 5 apatite; # 5 b-tri calcium phosphate (TCP); þ 5 a-TCP).
Figure 4. Microcomputed tomography (lCT) images of CaP implants containing 5% (A), 10% (B), 20% (C) PLGA 101–200
lm sizes. Together with 20% PLGA 0–200 lm sizes (D) used for the early implantation periods (short-term biocompatibil-
ity). PLGA microparticles appear as pores in the CaP cement. The size of each sample is 0.5 3 0.5 3 0.5 mm3.
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Statistical analyses
Statistical analyses were performed with GraphPad1
Instat 3.05 software (GraphPad Software, San Diego, CA)
using a one-way analysis of variance (ANOVA) with a
post-hoc Tukey multiple comparisons test.
RESULTS
Implant characterization
The microporosity of the various implant formula-
tions varied between 6.5% and 57.1%, showing lowest
values for implants containing 5% PLGA small-sized
and highest values for implants containing 20%
PLGA large-sized microparticles (Fig. 2). XRD analy-
sis demonstrated that the CaP0 discs were mainly
composed of a-tri calcium phosphate (a-TCP). Prein-
cubation of the discs for eight weeks in water (CaP8)
resulted in the hydrolysis of a-TCP into an apatite-
like structure with some b-TCP. After implantation,
the structure of the CaP8 samples remained the same,
whereas the CaP0 samples underwent hydrolysis of
a-TCP into an apatite-like structure without b-TCP
formation (Fig. 3). The incorporation of PLGA micro-
particles did not induce alterations of XRD patterns
compared to pure CaP samples.
Microcomputed tomography (lCT) indicated inter-
connectivity within all samples containing 20% (w/
w) PLGA, except for those with small diameter (0–
50 lm) microparticles (Fig. 4).
In vivo studies
All 52 rats in this experiment remained in good
health and did not show any wound complications.
At retrieval, the 12- and 24-week implants were sur-
rounded by a macroscopically visible fibrous cap-
sule. All implants had retained their structural integ-
rity, and no inflammatory signs or adverse tissue
reactions were observed.
Short-term biocompatibility
Light microscopic analysis of the histological sec-
tions revealed that a fibrous tissue capsule devel-
oped around all implants in time. Furthermore,
Figure 5. Histological sections of CaP implants containing 20% PLGA microparticles after 4 days (A and B) and 12 days (C
and D) of implantation. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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inflammatory cells were present during all implanta-
tion periods (2, 4, 8, and 12 days), but amounts were
declining in time. No multinucleated cells were
observed within any of the different implant formu-
lations (CaP0, CaP0/PLGA, CaP8, and CaP8/PLGA).
CaP/PLGA cements, whether or not preincubated in
water, did not contain fibrous tissue throughout the
implants, but only concavities on the surface of the
implants were filled with fibrous tissue.
After 2 days of implantation, inflammatory cells
were observed in the implant vicinity without a con-
nective tissue capsule around any of the implants.
After 4 days [Fig. 5(A,B)], a thin connective tissue
capsule had developed, containing inflammatory
cells with some fibroblasts and a small amount of
collagen bundles. After 8 days, the amount of colla-
gen and number of fibroblasts increased in the thin
connective tissue capsule and still few inflammatory
cells were present. At 12 days [Fig. 5(C,D)], the thin
fibrous capsule had not increased in size and the
amount of fibroblasts and inflammatory cells
appeared to be similar as for the 8-days implants.
Quantitative histological evaluation (Fig. 6)
revealed that no significant differences in capsule
and interface scores were present between the differ-
ent formulations of implants (CaP0, CaP0/PLGA,
CaP8, and CaP8/PLGA) at individual time points.
On the other hand, capsule quality scores of the
CaP0 and CaP8/PLGA group were significantly dif-
ferent between 4 and 12 days, both showing the
transformation of a granulous and dense capsule
containing fibroblasts and inflammatory cells into a
mature capsule resembling connective tissue [Fig.
6(A)]. Furthermore, capsule quantity scores of the
CaP8/PLGA group between 4 and 8 days were sig-
nificantly different, showing an increase in the num-
ber of fibroblast layers from 1 to 4 at day 4 to 5 to 9
fibroblast layers at day 8 [Fig. 6(B)]. Finally, capsule
interface scores were significantly different between
days 4 and 12 in the CaP0/PLGA group, where
inflammatory cells contacting the surface of the
implants were replaced by fibroblasts [Fig. 6(C)].
Long-term biocompatibility
All implant formulations (CaP with 5, 10 or 20%
w/w PLGA and small, medium, or large micropar-
ticle sizes) were surrounded by a connective tissue
capsule containing fibroblasts, collagen bundles and
few inflammatory cells after 12 weeks of implanta-
tion (Fig. 7). No multinucleated cells were observed
within any of the different implant formulations.
Similar observations were made after 24 weeks of
implantation. Furthermore, only few inflammatory
cells were present in the pores of the implants,
Figure 6. Histological evaluation of capsule quality (A), capsule quantity (B) and interface quality (C) of the short-term
biocompatibility samples using the histological grading scale. Data shown represent mean 6 sd. Significant differences
(p < 0.05) are indicated with an asterisk (*).
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which were created after hydrolysis of PLGA micro-
particles. The implants containing 20% PLGA with
medium- and large-sized microparticles showed fi-
brous tissue ingrowth throughout the implants [Fig.
7(C,D)], indicating PLGA degradation and intercon-
nectivity of the pores. This is in contrast to all 5%
and 10% PLGA formulations, and 20% PLGA formu-
lations with small-sized microparticles, which only
showed fibrous tissue ingrowth at the implant pe-
riphery. Quantitative histological evaluation revealed
that no significant differences in capsule and inter-
face scores were present between the different
implant formulations (CaP with 5, 10, or 20% w/w
PLGA and small, medium, or large microparticle
sizes) at individual time points (Fig. 8).
DISCUSSION
This biocompatibility study was performed to
exclude that the incorporated PLGA microparticles
evoked an inflammatory response. Therefore, the
short and long-term biocompatibility of CaP/PLGA
formulations was examined using a subcutaneous
implantation model in rats.
Physicochemical analysis demonstrated that due
to implantation or preincubation in water, the a-TCP
component in the CaP cement undergoes hydrolysis
resulting in transformation into an apatite-like struc-
ture. After implantation, CaP cement hydrolysis was
more pronounced in preincubated samples com-
pared to nonpreincubated samples. This might be
due to a longer exposure time (8 weeks) of preincu-
bated samples to water, the difference between body
fluids and only water, or a combination of both.
Histological and histomorphometrical evaluation
showed only a mild tissue response to any of the
different CaP/PLGA composites formulations in the
early implantation periods (2, 4, 8, and 12 days). No
differences in vivo were observed between pure CaP
cement and CaP cement incorporating PLGA micro-
particles, whether or not preincubated in water.
Implant preincubation was based on the results of a
previous in vitro study,13 which showed that without
Figure 7. Histological sections of CaP implants containing 10% PLGA 101–200 lm sizes (A and B) and 20% PLGA 51–100 lm
sizes (C and D) after 24 weeks of implantation. Arrows indicate fibrous tissue ingrowth. [Color figure can be viewed in
the online issue, which is available at www.interscience.wiley.com.]
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preincubation in water, CaP cement was not physi-
cochemically stable. This resulted in the release of
ionic species, which caused cell death. The preincu-
bation of CaP cement resulted in the hydrolysis of a-
TCP into an apatite-like structure, which favored the
biological response. However, the preincubated CaP
cement still was not cytocompatible in vitro.13 Never-
theless, the in vivo results of the current study did
not indicate a detrimental effect of formulations
without preincubation on cells/tissues. Apparently,
the capacity to buffer ionic species in vivo is higher
than in in vitro experiments. Although PLGA is
regarded as a nontoxic and biocompatible material,19
it is known that PLGA microparticles larger than
10 lm in diameter can evoke a foreign body reaction
at the surface of these microparticles.11,20 These data
do not confirm the results of the current study, as no
inflammatory response to PLGA microparticles was
observed with various (1–200 lm).
The microporosity in the CaP cement was created
by incorporation and subsequent in vivo hydrolysis
of PLGA microparticles. However, incorporation of
microparticles is not a guarantee to achieve intercon-
nectivity in the composites. In the present study, fi-
brous tissue ingrowth after 24 weeks throughout the
implant indicated complete PLGA degradation and
interconnectivity in the formulations containing 20%
PLGA with medium and large microparticles.
Recently, Habraken et al. showed that in vitro degra-
dation of PLGA microparticles started after 6 weeks
and was completed after 12 weeks. However, the
reduction in molecular weight of the PLGA already
started at day 0 and was 80% at 6 weeks when mass
loss was visible.16 Therefore, the PLGA micropar-
ticles encapsulated in the CaP cement maintained
their structure until 6 weeks, although molecular
weight loss already commenced. In the current
study, complete degradation of PLGA microparticles
could only be evidenced by fibrous tissue ingrowth
throughout the implants after 12 and 24 weeks.
Interestingly, in the implants containing 10% w/w
PLGA with large microparticles, no fibrous tissue
inside the implants was observed. This might indi-
cate that within this CaP/PLGA formulation the
Figure 8. Histological evaluation of capsule quality (A), capsule quantity (B), and interface quality (C) of the long-term
biocompatibility samples using the histological grading scale. Data shown represent mean 6 sd.
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micropores were not interconnected. However, the
porosity of 50.1% 6 0.7% in these implants was
higher compared to the 36.2% 6 1.9% porosity of in
the implants with 20% PLGA with medium micro-
particles. This suggests that interconnectivity does
not depend solely on larger particles, but also on
smaller particles as a connecting agent. The most
ideal might be a mixture of smaller and larger
microparticles, where smaller particles can act as a
connecting agent between the larger particles to cre-
ate an interconnected network. The interconnectivity
in the composites with 20% PLGA with medium and
large microparticles corroborates other studies indi-
cating the necessity of pores of at least 50 lm to
obtain optimal porosity of porous ceramics.21 Micro-
computed tomography also indicated interconnectiv-
ity between the samples of 20% PLGA with medium
and large sized microparticles. By applying a thresh-
old to the images, the CaP cement was extracted
form the original image. Because of reasons of arbi-
trary threshold as a result of alternating ranges and
intensities of individual sample grey scales, lCT was
not applicable for quantification of porosity and
interconnectivity.22,23 Therefore, lCT was only used
to visualize the appearance of the samples.
Remarkably, a study by Ruhe´ et al. indicated that
CaP cement possesses a certain degree of intrinsic
osteoinductive properties, as they found mineralized
extracellular matrix in pores after PLGA degrada-
tion.10 However, that study consisted of smaller
CaP/PLGA implants (2.0 mm height and 3.5 mm di-
ameter) together with larger PLGA microparticles
(73 6 27 lm) combined with CO2 induced macro-
pores, which together gave a heterogeneous distribu-
tion of macropores. Although, the current study was
not designed to examine possible osteoinductivity of
CaP cement, none of the composite formulations
showed any formation of bone upon subcutaneous
implantation. However, these observations do not
exclude osteoinductive properties of CaP cement,
since factors like species, implant location, and
implant size are known to influence the formation of
bone tissue at ectopic sites.24,25
CONCLUSIONS
The results of the present study demonstrate that
CaP/PLGA composites evoke a minimal inflamma-
tory response. The implants containing 20% PLGA
with medium- and large-sized microparticles showed
fibrous tissue ingrowth throughout the implants after
12 and 24 weeks indicating PLGA degradation and
interconnectivity of the pores. Therefore, CaP/PLGA
composites can be regarded as biocompatible bioma-
terials with potential for bone tissue engineering and
advantageous possibilities of the microparticles
regarding material porosity.
We would like to thank the Dutch Technology Founda-
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